Morningstar Investment Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Morningstar Investment Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-83,831	Closed	-$13.9M	–	219
2022 Q1	$13.9M	Buy	83,831 +1,264	+2%	+$193K	0.15%	106
2021 Q4	$14M	Buy	82,567 +1,973	+2%	+$367K	0.16%	106
2021 Q3	$14.3M	Buy	80,594 +1,427	+2%	+$268K	0.17%	102
2021 Q2	$13.1M	Buy	79,167 +2,617	+3%	+$383K	0.16%	104
2021 Q1	$10.3M	Buy	+76,550	New	+$11.5M	0.13%	115

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morningstar Investment Services's ALNY Position: Q2 2022 in Review

Morningstar Investment Services sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 83,831 shares — an estimated $13.9M sold.

Morningstar Investment Services first reported a position in ALNY in Q1 2021 and held it in 5 quarters. The position peaked at $14.3M in Q3 2021. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

Morningstar Investment Services reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Morningstar Investment Services sold 83,831 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $13.9M.
Morningstar Investment Services first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Morningstar Investment Services's Alnylam Pharmaceuticals position peaked at $14.3M in Q3 2021.
423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Morningstar Investment Services's 13F filing for Q2 2022, filed 12 Aug 2022.